Breast cancer biotech Merus files for a $60 million IPO

Merus, which is developing bispecific antibody treatments for solid tumors, filed on Monday with the SEC to raise up to $60 million in an initial public offering. 

The Utrecht, Netherlands-based company, which was founded in 2003 and booked $2 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol MRUS. Merus initially filed confidentially on 9/8/2015. Citi, Jefferies, Guggenheim Securities and Wedbush PacGrow are the joint bookrunners on the deal. No pricing terms were disclosed.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.